U.S. Professional Services Stock News

Lovesac (LOVE) just posted its Q3 2026 numbers, with revenue at about $150 million and basic EPS of -$0.72, alongside a trailing twelve month EPS of $0.49 that reflects modest overall earnings progress over the past year. The company has seen quarterly revenue move between roughly $138 million and $161 million over the last few periods, while quarterly EPS has swung from -$0.73 to $2.31 and back into the red, underscoring a business where profitability is still choppy even as the longer term...

If you have been wondering whether Ball is quietly turning into a value opportunity or just a value trap, you are in the right place to unpack what the current share price is really telling us. Despite being down 9.6% year to date and 13.8% over the last year, the stock has shown some short term resilience, with a 0.7% gain over the past week and a 4.1% rise over the last month from its recent close around $49.21. Recent headlines have focused on Ball sharpening its portfolio and capital...

Wondering if Medpace Holdings is still worth buying after its huge run, or if the smart move now is to wait for a better entry point? You are not alone, and that is exactly what we are going to unpack here. The stock has pulled back about 6.1% over the last month after a strong year to date jump of 69.1%, and a hefty 63.0% gain over the past year. Zooming out further, Medpace is up 175.1% over three years and 279.5% over five, which naturally raises the question of how much upside is...

Oracle (ORCL) has just posted a hefty Q2 2026 print, with revenue at about $16.1 billion, basic EPS of $2.14 and net income (excluding extra items) of roughly $6.1 billion setting the tone for this earnings season. The company has seen revenue climb from about $14.1 billion in Q2 2025 to $16.1 billion in Q2 2026, while EPS moved from $1.13 to $2.14 over the same period. This puts solid historical context around the latest numbers and sets up a story where expanding profit margins take center...

Church & Dwight (CHD) has been sliding this year, with the stock down nearly 20% year to date as investors reassess how much they are willing to pay for its steady but slower growth profile. See our latest analysis for Church & Dwight. At a share price of $83.57, Church & Dwight’s year to date share price return of negative 19.5 percent and one year total shareholder return of negative 19.7 percent signal fading momentum as investors cool on its premium valuation, despite still solid earnings...

Nomad Foods (NOMD) just delivered a weaker than expected quarter, as record warmth weighed on frozen food demand and rising input costs squeezed margins, making the stock a clear drag for at least one institutional strategy. See our latest analysis for Nomad Foods. The stock’s 30 day share price return of 4.10% suggests a tentative bounce, but the year to date share price decline of 25.33% and 12 month total shareholder return of 26.77% highlight fading momentum as investors reassess...

Wondering if Organon at around $7 is a deep value opportunity or a value trap? You are not alone. This stock has quietly slipped onto a lot of bargain hunters' watchlists. Despite being down about 50.8% year to date and over the last 12 months, the share price has shown some short term resilience, with a 3.1% gain over the past week even after a soft 30 day move of -2.1%. Much of this volatility has been driven by shifting sentiment around its women’s health and biosimilars portfolio, as...

Rithm Capital (RITM) is back in focus after a fresh wave of strategic moves, from buying Crestline and Sculptor to exploring a spin off of its origination and servicing operations. See our latest analysis for Rithm Capital. Despite the recent pullback in its 90 day share price return, Rithm’s steady year to date share price gain and strong multi year total shareholder returns suggest sentiment is still constructive as investors weigh these expansion moves and spin off optionality. If Rithm’s...

Wondering if Cognex at around $36.88 is a bargain in disguise or a value trap in plain sight? This article walks through what the numbers are really saying about the stock. Despite being up 3.3% year to date, Cognex shares have slipped 5.2% over the last week and 4.0% over the last month, capping off a much rougher 3-year slide of 23.6% and a 52.3% drop over 5 years that has clearly reset expectations. Recent moves have come as investors reassess machine vision and factory automation names...

Planet Labs PBC (PL) just posted another quarterly update with Q3 2026 revenue of about $81.3 million, basic EPS of roughly -$0.19, and trailing-12-month revenue sitting near $282.5 million alongside TTM EPS of around -$0.43. This keeps the profitability story clearly in the red even as the top line builds. The company has seen revenue move from about $61.3 million in Q3 2025 to $81.3 million in Q3 2026, while quarterly EPS has slid from roughly -$0.07 to -$0.19 over the same stretch,...

In early December 2025, Sprinklr reported third-quarter revenue of US$219.07 million and net income of US$2.9 million, alongside new fourth-quarter and full-year 2026 revenue guidance of US$216.5–217.5 million and US$853–854 million, respectively. Award recognition from ADWEEK and L’Oréal’s large-scale use of Sprinklr Advocacy, which generated very large organic impressions and a 4x return on investment, underline how major brands are using Sprinklr’s AI-native platform to run social media,...

If you are wondering whether Allegion at around $164 a share is still a smart buy or if the easy gains are behind it, this breakdown will help you decide whether the current price makes sense. The stock is up 2.4% over the last week and 28.1% year to date, even after a modest 1.7% dip over the past month. This suggests that the market still sees solid long term potential in the story. Recent headlines have focused on Allegion expanding its presence in electronic and IoT enabled security...

On 9 December 2025, CorMedix director Steven W. Lefkowitz sold 40,000 shares of common stock for about US$475,200, leaving him with 80,498 shares, shortly after the company reported Q3 2025 earnings and revenue that significantly exceeded market forecasts. The combination of robust quarterly results and insider selling draws attention to how CorMedix’s recent operational momentum aligns with leadership’s portfolio decisions. With CorMedix’s Q3 earnings beating expectations, we’ll examine how...

Keurig Dr Pepper (KDP) has been quietly grinding higher, with the stock up about 10% over the past month and 8% in the past 3 months, even as its year to date return remains negative. See our latest analysis for Keurig Dr Pepper. That recent 30 day share price momentum of just over 10% is starting to chip away at a tougher year to date patch, even though the one year total shareholder return is still slightly negative. This suggests sentiment may be cautiously turning as investors reassess...

Perdoceo Education (PRDO) has quietly pulled back almost 9% over the past month even as its longer term track record and steady revenue and earnings growth paint a very different picture for patient investors. See our latest analysis for Perdoceo Education. The recent slide looks more like a breather than a breakdown, with a 30 day share price return of negative 8.9% coming after a solid year to date share price gain and a standout three year total shareholder return above 120%. This suggests...

Amtech Systems (ASYS) has just posted its FY 2025 fourth quarter numbers, with revenue of about $19.8 million and EPS of roughly $0.07 setting the tone for the latest print. Over the past six quarters, the company has seen quarterly revenue move from about $24.1 million in Q4 2024 to a peak of $26.7 million in Q3 2024 before landing at $19.8 million in Q4 2025. Over the same period, EPS has swung from a loss of roughly $0.04 in Q4 2024 to a deep trough of about negative $2.23 in Q2 2025 and...

RedCloud Holdings (NasdaqCM:RCT) just posted its H1 2025 scorecard, with trailing twelve month revenue of about $48.4 million and a basic EPS of roughly -$1.76. This sets a clear backdrop of rapid top line expansion paired with ongoing losses. The company has seen revenue move from $13.6 million in H2 2023 to $16.1 million in H1 2024 and then $30.4 million in H2 2024. Over those same halves, EPS shifted from about -$4.20 to -$0.51 and then a much steeper -$17.85. That combination of fast...

Vail Resorts (MTN) opened fiscal Q1 2026 with revenue of about $271 million, a basic EPS loss of roughly $5.20, and net income excluding extra items of around negative $187 million, setting a cautious tone for the new season. The company has seen quarterly revenue move from about $260 million in Q1 2025 to roughly $271 million in Q1 2026, while basic EPS shifted from a loss of about $4.62 to a loss of roughly $5.20 over the same period, giving investors a mixed read on top line stability...

Bel Fuse (BELF.A) has quietly put up a strong run lately, with the stock gaining about 22% over the past month and more than 31% in the past 3 months. See our latest analysis for Bel Fuse. Zooming out, the recent rally fits into a much bigger move, with a strong year to date share price return helping push Bel Fuse to around $155.40 as investors warm to its growth trajectory and reassess risk. If Bel Fuse’s momentum has you rethinking your tech exposure, it might be a good moment to scan...

If you have been wondering whether SkyWest at around $107 a share is still good value after its big comeback, you are not alone. This article is designed to walk you through that question step by step. The stock has climbed 5.2% over the last week, 10.6% over the past month, and 495.2% over three years, which naturally raises the question of how much upside, or downside, might be left from here. Recently, investors have been focused on SkyWest’s progress in rebuilding regional capacity and...

Manchester United (NYSE:MANU) opened Q1 2026 with revenue of about £140.3 million and a basic EPS of roughly -£0.04, alongside net income of around -£6.6 million, keeping the club in loss-making territory even as it reports another busy quarter of activity. The club has seen quarterly revenue move between roughly £143.1 million and £198.7 million over the past year while EPS has swung from £0.01 to as low as about -£0.16, which sets up a narrative where a growing top line and negative EPS...

Wondering if Bloom Energy is still worth buying after its massive run up, or if the easy money has already been made? Let us break down what the recent action really implies for its underlying value. Despite a sharp pullback over the last week and month, with returns of -7.7% over 7 days and -14.2% over 30 days, the stock is still up an eye catching 366.4% year to date and 339.3% over the past year, with multi year gains above 300%. These swings have come as investor attention has shifted...

Payoneer recently announced a partnership with Oscilar, integrating its AI- and machine-learning-based fraud and risk intelligence platform across Payoneer’s core global payment systems to improve predictive monitoring and automation. This upgrade in fraud prevention aims to tighten risk controls while keeping customer interactions smooth, which could strengthen Payoneer’s competitive position in cross-border payments for small and medium-sized businesses. Next, we’ll examine how Payoneer’s...

Savara Inc. recently announced that the European Patent Office intends to grant a patent covering the liquid formulation of MOLBREEVI, its orally inhaled GM-CSF therapy delivered via the eFlow Nebulizer System for the rare lung disease autoimmune pulmonary alveolar proteinosis. This prospective patent, alongside multiple expedited and orphan designations in the U.S., EU and U.K., could materially extend MOLBREEVI’s protection and enhance the company’s respiratory disease franchise if...